文献速递前列腺癌

骨生物标志物与激素敏感性前列腺癌男性后续生存:SWOG S1216 三期试验结果——雄激素剥夺治疗联合或不联合奥尔特罗尼

Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel.
PubMed 文献 · Eur Urol · 2023-04-19

SWOG S1216 三期试验评估激素敏感性前列腺癌(HSPC)患者基线骨生物标志物与总生存(OS)的关系。1279 例中 949 例可评估,四种骨转换标志物升高均与更差 OS 相关,校正临床因素后死亡风险比为 1.37 至 1.92;基于标志物组合划分的低、中、差三组中位 OS 分别为 8.2、5.1、2.1 年,并在验证集中确认。

要点

  • HSPC 患者基线骨吸收与骨形成标志物升高与更差 OS 独立相关,风险比 1.37 至 1.92。
  • 基于四种骨生物标志物组合可划分低、中、差三个风险组,中位 OS 分别为 8.2、5.1、2.1 年。
  • 上述预后价值在验证集中得到确认,将骨标志物应用从去势抵抗状态扩展至激素敏感状态。

核心结论

  • 在接受雄激素剥夺治疗的 HSPC 男性中,骨生物标志物对 OS 具有强且独立的预后价值。
  • 骨生物标志物单独或联合临床协变量可识别 OS 结局不同的独特患者亚组。
  • 这些结果验证了骨生物标志物评估在 HSPC 状态下的临床价值,将其效用扩展至去势抵抗状态之外。

研究设计与样本

  • 前瞻性评估骨生物标志物的三期随机研究,比较雄激素剥夺治疗联合或不联合 CYP17 抑制剂奥尔特罗尼。
  • 患者随机分为训练集(n=316)和验证集(n=633),采用递归分割和 Cox 比例风险模型分析。
  • 从患者血清中检测骨吸收标志物(C-端肽和吡啶啉)和骨形成标志物(C-端胶原前肽和骨碱性磷酸酶)。
  • 1279 例男性中 949 例有可评估的基线骨生物标志物。

主要发现

  • 确定四种骨生物标志物升高的最佳截断值(均 p < 0.05),均与更差 OS 相关。
  • 在验证集中校正临床危险因素后,骨生物标志物升高与死亡风险增加呈统计学显著相关,风险比范围为 1.37 至 1.92。
  • 对训练集应用递归分割算法,基于骨生物标志物组合识别出三个风险组(低、中、差),中位 OS 分别为 8.2、5.1 和 2.1 年。
  • 上述结果在验证集中得到确认。

关键数值与推荐

  • 四种骨生物标志物升高的最佳截断值均与更差 OS 相关(均 p < 0.05)。
  • 验证集中校正临床危险因素后,骨生物标志物升高与死亡风险增加相关,风险比范围为 1.37 至 1.92。
  • 基于骨生物标志物组合划分的低、中、差风险组中位 OS 分别为 8.2、5.1 和 2.1 年。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bone biomarkers are strongly prognostic for overall survival (OS) in men with castration-resistant prostate cancer but not fully established for hormone-sensitive prostate cancer (HSPC). OBJECTIVE: Bone biomarkers in HSPC were prospectively evaluated as part of a phase 3 study of androgen deprivation therapy ± the CYP17 inhibitor orteronel. DESIGN, SETTING, AND PARTICIPANTS: Patients were randomly divided into training (n = 316) and validation (n = 633) sets. Recursive partitioning and Cox proportional hazard models were employed. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Bone resorption (C-telopeptide and pyridinoline) and bone formation markers (C-terminal collagen propeptide and bone alkaline phosphatase) were assessed from patient sera. RESULTS AND LIMITATIONS: Of 1279 men, 949 had evaluable baseline bone biomarkers. Optimal cutoffs were identified to define elevated levels of each of the four biomarkers (all p < 0.05) that were associated with worse OS. After adjusting for clinical risk factors in the validation set, elevated bone biomarkers were statistically significantly associated with an increased risk of death (hazard ratios ranging from 1.37 to 1.92). Recursive partitioning algorithms applied to the training set identified three risk groups (low, intermediate, and poor) with differential OS outcomes (median OS: 8.2, 5.1, and 2.1 yr, respectively) based on combinations of bone biomarkers. These results were confirmed in the validation set. CONCLUSIONS: In men with HSPC initiating androgen deprivation therapy, bone biomarkers are strongly and independently prognostic for OS. Bone biomarker levels alone or in combination with clinical covariates identify unique subsets of men with differential OS outcomes. These results validate the clinical value of bone biomarker assessment in the HSPC state, extending bone biomarker utility beyond the castration-resistant state. PATIENT SUMMARY: In men with newly diagnosed metastatic prostate cancer, high levels of bone turnover biomarkers are associated with a shorter lifespan.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Lara PN, Mayerson E, Gertz E, et al. Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel. Eur Urol. 2023. PMID: 37085425. doi:10.1016/j.eururo.2023.03.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。